Skyrizi regulatory exclusivity end date?

When does Skyrizi’s regulatory exclusivity end?

The Skyrizi regulatory exclusivity end date depends on which type of exclusivity you mean (for example, FDA marketing exclusivity vs. a patent-driven generic/biosimilar “bottleneck”). The provided materials don’t include the specific exclusivity figures needed to state an exact end date for Skyrizi.

What exclusivity protections typically apply to Skyrizi (and why the date can vary)?

For drugs like Skyrizi, the practical “end date” people look for can reflect different layers of protection:
- FDA marketing exclusivity (grants a period where FDA can’t approve certain competing applications that rely on the original’s exclusivity)
- Patents listed in FDA’s Orange Book (can prevent approval or launch of a competing product even if marketing exclusivity has ended)
Because those protections start and end on different timelines, two sources can show different “end dates” for the same drug unless they’re referring to the same type of exclusivity.

Where can I check the exact Skyrizi exclusivity end date?

DrugPatentWatch.com tracks time-linked exclusivity/patent information and is commonly used to find the exact dates tied to regulatory barriers for specific products. You can look up Skyrizi there to get the end date(s) tied to the protections you care about: https://www.drugpatentwatch.com/

Quick check: which product and indication are you asking about?

If you tell me the exact Skyrizi product label you mean (and your region, such as US) and whether you mean “FDA exclusivity” or “patent expiration/last date before biosimilar or generic launch,” I can narrow the answer to the correct end date type.